Short report on the North American Hair Research Society annual conference, Bar Harbor, Maine, USA
hair growth news logo
Hair Biology News
Pattern Hair Loss News
Hair Restoration News
Hair Cosmetics News
Alopecia Areata News
Hirsutism Hypertrichosis News
Other Hair Conditions News
Hair Color News
Bits and Pieces News


Short report on the North American Hair Research Society annual conference, Bar Harbor, Maine, USA

The Bar Harbor conference was basic hair biology oriented so not really directed at finding treatments for hair loss diseases. We had reviews on gene expression and techniques for locating genes in disease, extensive reviews on hair follicle morphology and also comparison of hair follicles to nails and teeth as related skin structures.

The highlights included Dr Christiano talking about the hairless gene. This has been demonstrated not to be involved in androgenetic alopecia. DR Christiano's team have been applying the hr mutant gene to normal mice as a gene therapy. The application inhibited hair growth. Although at the (very) experimental stage, DR Christiano suggested it might be a possible gene therapy to treat excess hair growth. DR Christiano has now identified several different forms of hairless gene mutation in humans and several individuals previously diagnosed as having alopecia areata were found to have a hairless gene mutation after testing (congenital or papular atrichia).

DR Elise Olsen gave a review of androgenetic hair loss in women and suggested that the ludwig grading system was not a good categorization method for female pattern baldness. She suggested a more complex categorization system based on hair parting width and the amount of hair loss in the frontal vertex region. This system is to be published shortly.

Of interest to me was an announcement during the conference that a grant application to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to set up a central DNA repository for alopecia areata research had been awarded. The will involve funding worth $2.7 million over a 5 year period. The following are the sites of the registry; University of Texas, Houston, University of Colorado Health Sciences Center, Denver Columbia University, New York, New York, University of Minnesota, Minneapolis, and University of California, San Francisco.

Genes and gene therapy was a big focus at the conference. Several seminars discussed gene expression during the hair cycle and showed that several wnt genes and the Noggin gene are fundamentally involved in hair cycling and growth. Gene therapy reviewed by Lorne Taichman showed that in principle it is possible to transfect hair follicle cells with genes and have gene expression persist for at least 16 weeks. His team transfected a lacZ reporter gene into mouse hair follicles and the gene activity was still present, albeit in a patchy manner, 16 weeks later. They are confident they had transfected hair follicle stem cells given the expression lasted so long.

Maybe of most interest to you would have been the talk by Keith Kaufman from Merck. He gave the typical review of Propecia, but a few slides he flashed up were new to me. The most recent results on Propecia show that the individuals who have been using for 5 years now are starting to have a decline in the hair density. Before the hair density had always gradually climbed year on year and the placebo users had progressively declined. However, both groups at year 5 had a drop in hair density although the Propecia users still have much more hair than the placebo users.

The typical anagen growth phase for scalp hair last 4-5 years. So it was suggested that the decline was because the hair follicles, under the control of Propecia, were entering a telogen phase at about the same time. Hair follicles cycle in a random mosaic pattern in humans but the cycle can be coordinated under the control of drugs like minoxidil and Propecia. I guess Merck will be hoping the hair density will bounce up again with next years results.

Merck very briefly discussed new treatments from themselves and Glaxo. Merck suggested there might be some dangers in using a type I and II 5 alpha reductase inhibitor such as Glaxo's Dutasteride and Turosteride drugs. The 5 alpha reductase inhibitors would lead to a significant
increase in testosterone and this could be transformed into estrogens by other enzymes in the body. Consequently, it was suggested that there could be an increased potential risk of estrogen disorders in Dutasteride users. Kaufman also briefly flashed up a slide on other potential drugs for androgenetic alopecia including "melformin" and "thiazolidinediones"

Copyright . All Rights Reserved www.hairgrowthnews.com